TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02009124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
Study: NCT03279939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
Study: NCT00266409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
Study: NCT00698100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human tyrosinase
Description: Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse tyrosinase
Description: Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
Study: NCT01963364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin challenge
Description: On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oligofructose supplement
Description: Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
Study: NCT01893138

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iltamiocel
Description: AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
Study: NCT02518230

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurally Adjusted Ventilatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurally Adjusted Ventilatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist

Intervention type: DEVICE
Group type: OTHER
Intervention: Synchronized Interm. Mandatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support

Intervention type: DEVICE
Group type: OTHER
Intervention: Synchronized Interm. Mandatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
Study: NCT03279939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Color Fundus Photography
Description: Non-contact white light photography.
Study: NCT00928837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavocoxid 500 mg
Description: flavonoid mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: non-steroidal anti-inflammatory drug
Study: NCT03279939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Color Fundus Photography
Description: Non-contact white light photography.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescein Angiography
Description: An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescein Angiography
Description: An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indocyaine Green Angiography
Description: An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
Study: NCT00928837

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flavocoxid 250 mg
Description: Medical food product
Study: NCT02154529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01524042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pants for colonoscopy
Description: We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
Study: NCT03502642

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)
Description: After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)
Description: After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Anesthesia
Description: Cesarean section was conducted under spinal anesthesia in both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Cesarean section was conducted under spinal anesthesia in both groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal morphine
Description: Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (Ropivacaina Molteni®)
Description: A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
Study: NCT02721732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01008787

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Weeks 4 and 8, 30 minute phone interview about mood and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Weeks 4 and 8, 30 minute phone interview about mood and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA Newsletter
Description: At Weeks 5 and 9, receive a physical activity (PA) newsletter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA Newsletter
Description: At Weeks 5 and 9, receive a physical activity (PA) newsletter.
Study: NCT04270045

Intervention type: DEVICE
Intervention: Non-invasive forced airway oscillometry
Description: This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
Study: NCT03587662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT02950766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: combination of Neoantigen peptides and poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: combination of Neoantigen peptides and poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: local administration of ipilimumab
Study: NCT01344993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
Study: NCT03587662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study: NCT03435952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium Novyi-NT
Description: Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
Study: NCT03587662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study: NCT00811902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, oral administration
Study: NCT01868698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-voltage electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shortwave diathermy
Study: NCT04280848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
Study: NCT05226806

Intervention type: OTHER
Intervention: Measurement of cardiorespiratory performance in 3 different settings
Description: The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks

Intervention type: OTHER
Intervention: GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES
Description: General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
Study: NCT02216240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT03395184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Placebo
Description: 12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
Study: NCT03286699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
Study: NCT03395184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PF-06700841
Description: 12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
Study: NCT00558220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consolidation treatment part 1: HD-chemotherapy with ASCT
Description: Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery.
Study: NCT03286699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
Study: NCT00558220

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation treatment part 2: Radiotherapy
Description: Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
Study: NCT01369706

Intervention type: DEVICE
Group type: OTHER
Intervention: Hand-held metal detector
Description: 2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
Study: NCT04481334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative occupational therapy interactive vaulting group
Description: Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
Study: NCT01751451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus degarelix
Description: Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.